90% CI riddle [Bioanalytics]

posted by The Outlaw Torn – Europe, 2012-12-20 12:23 (4542 d 20:42 ago) – Posting: # 9736
Views: 8,312

❝ By this every application for a generic with an "old" BE study can be rejected by retrospective application of the guideline regardless of the scientific justification for missing ISR.


Dear Dan, I am in agreement with you, though I tried to tone down my feelings above.:cool: It only takes one stubborn assessor to stick to the ISR requirement and you're screwed.

Concerning your comment above, how about repeat use procedures? Is it possible for the authorities to reject such applications because the studies that were initially accepted will now be rejected because they no longer abide by the new guideline? and that's despite the fact that the drug has been on the market for years (and therefore has been shown to be safe and effective)? This Q&A document provides no re-assurances regarding, I would assume, this common concern.

It does raise more questions than it lays to rest, I think.

Outlaw

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,674 registered users;
47 visitors (0 registered, 47 guests [including 10 identified bots]).
Forum time: 10:06 CEST (Europe/Vienna)

It’s difficult to work in a group
when you are omnipotent.    John de Lancie (as Q)

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5